Drug Trial Radar · NCT04223778
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
672
Actual
Start
Feb 18, 2020
Primary completion
Sep 8, 2021
Study completion Aug 26, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a protocol-specified antiretroviral regimen. The primary hypothesis is that a switch to MK-8591A will be non-inferior to continued treatment with baseline antiretroviral therapy (ART) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48.
Conditions
- HIV Infection
Interventions
DOR/ISLDrug
A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
ARTDrug
Baseline ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48Time frame: Week 48
- Percentage of Participants With One or More Adverse Events (AEs) up to Week 48Time frame: Up to ~48 Weeks
- Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48Time frame: Up to ~48 Weeks
Locations
78 sites in 15 countries. Site status is shown where the registry gives one.
Georgetown University Hospital ( Site 1018)
Washington D.C., District of Columbia
Midway Immunology and Research ( Site 1030)
Ft. Pierce, Florida
Orlando Immunology Center ( Site 1007)
Orlando, Florida
Bliss Healthcare Services ( Site 1025)
Orlando, Florida
Triple O Research Institute, P.A. ( Site 1026)
West Palm Beach, Florida
Chatham County Health Department ( Site 1043)
Savannah, Georgia
Northstar Healthcare ( Site 1002)
Chicago, Illinois
Kansas City CARE Health Center ( Site 1008)
Kansas City, Missouri
ID Care ( Site 1023)
Hillsborough, New Jersey
University of North Carolina at Chapel Hill ( Site 1042)
Chapel Hill, North Carolina
University of Pennsylvania ( Site 1038)
Philadelphia, Pennsylvania
Saint Hope Foundation, Inc. ( Site 1037)
Bellaire, Texas
North Texas ID Consultants, PA ( Site 1003)
Dallas, Texas
Texas Centers for Infectious Disease Associates P.A. ( Site 1022)
Fort Worth, Texas
The Crofoot Research Center, Inc. ( Site 1005)
Houston, Texas
Holdsworth House Medical Practice ( Site 2300)
Sydney, New South Wales, Australia
Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 2309)
Herston, Queensland, Australia
Melbourne Sexual Health Centre ( Site 2305)
Carlton, Victoria, Australia
Fiona Stanley Hospital ( Site 2301)
Murdoch, Western Australia, Australia
Southern Alberta HIV Clinic ( Site 1108)
Calgary, Alberta, Canada
Vancouver ID Research and Care Centre Society ( Site 1100)
Vancouver, British Columbia, Canada
Hamilton Health Sciences ( Site 1103)
Hamilton, Ontario, Canada
Maple Leaf Research ( Site 1112)
Toronto, Ontario, Canada
Toronto General Hospital - University Health Network ( Site 1105)
Toronto, Ontario, Canada
Clinique de Medecine Urbaine du Quartier Latin ( Site 1104)
Montreal, Quebec, Canada
Clinique Medicale L Actuel ( Site 1114)
Montreal, Quebec, Canada
Hospital Dr. Hernan Henriquez Aravena ( Site 1305)
Temuco, Araucania, Chile
Clinica Arauco Salud ( Site 1300)
Santiago, Santiago Metropolitan, Chile
Centro de Investigacion Clinica UC CICUC ( Site 1303)
Santiago, Santiago Metropolitan, Chile
Fundacion Valle del Lili ( Site 1201)
Cali, Valle del Cauca Department, Colombia
A.P.H. Paris, Hopital Saint Louis ( Site 2014)
Paris, France
Hopital de la Croix-Rousse ( Site 2027)
Lyon, Auvergne-Rhône-Alpes, France
Hopital Francois Mitterrand ( Site 2019)
Dijon, Cote-d'Or, France
CHU de Bordeaux- Hopital Saint Andre ( Site 2015)
Bordeaux, Gironde, France
CHU de Toulouse - Hopital Purpan ( Site 2004)
Toulouse, Haute-Garonne, France
CHU Hotel Dieu Nantes ( Site 2020)
Nantes, Loire-Atlantique, France
CHU de Rouen ( Site 2005)
Rouen, Seine-Maritime, France
ASST Fatebenefratelli-Ospedale Sacco ( Site 2200)
Milan, Italy
A.O.U. Universita degli Studi della Campania-Luigi Vanvitelli ( Site 2208)
Naples, Italy
Policlinico Gemelli Instituto di Clinica Chirurgica ( Site 2206)
Roma, Italy
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.